Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009004380 - METHOD AND USE OF CIRCULATING LEVELS OF ENDOCANNABINOID LIGANDS FOR THE DETERMINATION OF PATIENT IN NEED AND/OR SUITABLE FOR CB1R ANTAGONIST DRUG TREATMENT AS WELL AS METHOD FOR INDUCING WEIGHT LOSS/MAINTENANCE/GAIN

Publication Number WO/2009/004380
Publication Date 08.01.2009
International Application No. PCT/GB2008/050526
International Filing Date 01.07.2008
IPC
G01N 33/50 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
G01N 33/92 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
92involving lipids, e.g. cholesterol
G01N 33/94 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
94involving narcotics
G01N 33/53 2006.01
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
CPC
A61P 3/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
G01N 2800/02
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
02Nutritional disorders
G01N 2800/52
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2800Detection or diagnosis of diseases
52Predicting or monitoring the response to treatment; Prognosis
G01N 33/948
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
94involving narcotics ; or drugs or pharmaceuticals, neurotransmitters or associated receptors
948Sedatives, e.g. cannabinoids, barbiturates
Applicants
  • ASTRAZENECA AB [SE]/[SE] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BE, BF, BG, BH, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SY, SZ, TD, TG, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • ASTRAZENECA UK LIMITED [GB]/[GB] (MG)
  • CARLSSON, Bjorn, Carl, Lennart [SE]/[SE] (UsOnly)
  • KARLSSON, Cecilia [SE]/[SE] (UsOnly)
  • SJÖGREN, Sven, Olof, Ivar [SE]/[SE] (UsOnly)
Inventors
  • CARLSSON, Bjorn, Carl, Lennart
  • KARLSSON, Cecilia
  • SJÖGREN, Sven, Olof, Ivar
Agents
  • ASTRAZENECA INTELLECTUAL PROPERTY
Priority Data
60/947,73303.07.2007US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHOD AND USE OF CIRCULATING LEVELS OF ENDOCANNABINOID LIGANDS FOR THE DETERMINATION OF PATIENT IN NEED AND/OR SUITABLE FOR CB1R ANTAGONIST DRUG TREATMENT AS WELL AS METHOD FOR INDUCING WEIGHT LOSS/MAINTENANCE/GAIN
(FR) PROCÉDÉ ET UTILISATION DE NIVEAUX CIRCULANTS DE LIGANDS ENDOCANNABINOÏDES POUR LA DÉTERMINATION D'UN PATIENT AYANT BESOIN DE ET/OU APPROPRIÉ POUR UN TRAITEMENT PAR MÉDICAMENT ANTAGONISTE DE CB1R, AINSI QUE PROCÉDÉ POUR INDUIRE UNE PERTE/UNE CONSERVATION/UN GAIN DE POIDS.
Abstract
(EN)
The present invention relates to patient selection tools and methods (including personalised medicine). In particular, the present invention permits the im proved selection of a patient in need of treatment with a cannabinoid re ceptor (CB1R) antagoni st drug, based on the levels of circulating endogenous cannabinoi d ligands (endocannabi noids). One of the aspects of the invention is a method of select ing a mammal in need of weight loss and/or weight maintenance and/or pr evention of weight gain treatment with a CB1R antagonist drug which comprises determining the leve l of at least one circulating endogenous cannabinoid ligand in the mamma l, whereby to predict an in creased likelihood of response to the CB1R antagonist drug. Some of the benefits of this personalised medicine approach include the ability to identify patients that are more likely to respond favourably to CB1R antagonist drug treatment and to identify pa tients less likely to respond to the drug treatment thus avoiding unnecessary treatment and any side eff ects that may be associated with such ineffective treatment.
(FR)
La présente invention porte sur des outils et des procédées de sélection de patient (comprenant la médecine personnalisée). En particulier, la présente invention permet la sélection améliorée d'un patient ayant besoin d'un traitement par un médicament antagoniste des récepteurs cannabinoïdes (CB1R), basée sur les niveaux de ligands cannabinoïdes endogènes circulants (endocannabinoïdes). L'un des aspects de l'invention est un procédé de sélection d'un mammifère ayant besoin d'un traitement de perte de poids et/ou de conservation de poids et/ou de prévention de gain de poids par un médicament antagoniste de CB1R qui comprend la détermination du niveau d'au moins un ligand cannabinoïde endogène circulant dans le mammifère, pour ainsi prédire une probabilité accrue de réponse au médicament antagoniste de CB1R. Certains des avantages de cette approche de médecine personnalisée comprennent l'aptitude à identifier des patients qui sont plus susceptibles de répondre favorablement à un traitement par un médicament antagoniste de CB1R et à identifier des patients moins susceptibles de répondre au traitement par un médicament, évitant ainsi un traitement non nécessaire et tout effet secondaires qui peuvent être associés à un tel traitement inefficace.
Latest bibliographic data on file with the International Bureau